Preclinical Data from REGENXBIO RGX-314 Gene Therapy Program for Wet Age-Related Macular Degeneration to be Presented at Upcoming Conferences

  • Preclinical data for RGX-314 program for the treatment of wet AMD to be presented at the Retinal Cell and Gene Therapy Innovation Summit, the Association for Research in Vision and Ophthalmology, and the American Society for Gene and Cell Therapy
  • Data support the active IND for RGX-314 Phase I clinical trial   

ROCKVILLE, Md., May 04, 2017 (GLOBE NEWSWIRE) — REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that preclinical data from studies supported by REGENXBIO at the University of Pennsylvania’s Gene Therapy Program and Center for Advanced Retinal and Ocular Therapeutics and at the Johns Hopkins Wilmer Eye Institute will be shared in one presentation and four posters at upcoming conferences including the Retinal Cell and Gene Therapy Innovation Summit, the Association for Research in Vision and Ophthalmology (ARVO), and the American Society of Gene and Cell Therapy (ASGCT). These data support further clinical research regarding the use of REGENXBIO’s investigational gene therapy RGX-314 for the treatment of wet age-related macular degeneration (wet AMD).

“RGX-314 has the potential to be a one-time treatment for people with wet AMD by delivering high expression of anti-VEGF antibodies through the use of our NAV AAV8 vector. We are pleased to share additional positive preclinical results, which were generated by our development partners at the University of Pennsylvania and Johns Hopkins, which support our active IND,” said Kenneth T. Mills, President and Chief Executive Officer of REGENXBIO. “REGENXBIO is on track to begin enrollment in the RGX-314 Phase I clinical trial by mid-2017 and to provide an interim trial update by the end of 2017.”….
Read more: